BioCentury
ARTICLE | Company News

NICE issues draft guidance against Cometriq and Caprelsa

September 1, 2017 3:12 PM UTC

NICE issued draft guidance recommending against the use of two drugs to treat medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease. The committee said clinical trial evidence showed Cometriq cabozantinib from Ipsen Group (Euronext:IPN; Pink:IPSEY) and Caprelsa vandetanib from Sanofi (Euronext:SAN; NYSE:SNY) were "effective" in delaying disease progression but they may not extend life expectancy. NICE added that the cost-effectiveness estimates are higher than acceptable for routine NHS use.

Neither drug met the end-of-life criteria, and both will be excluded from the U.K. Cancer Drugs Fund...